Precision BioSciences, Inc. DTIL
7.05 USD -0.23 (-3.16%)
Regular-session close
7.05 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
6.88 Day range 7.46
3.53 52-week range 11.29
- YTD
- +69.47%
- 1 year
- +37.16%
News
seekingalpha.com Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B Transcript Precision BioSciences, Inc. ( DTIL ) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B November 9, 2026 8:00 AM EST Company Participants Naresh Tanna - Chief Financial Officer…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
businesswire.com Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
businesswire.com Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…benzinga.com UPDATE: Precision BioSciences Q3 Adj. EPS $(0.74) Beats $(0.85) Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.85) by 12.94 percent. This is a 59.78 percent increase over losses…
benzinga.com Precision BioSciences Q3 EPS $(0.28) Beats $(0.85) Estimate Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.85) by 67.06 percent. This is a 84.78 percent increase over losses…
businesswire.com Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
defenseworld.net Precision BioSciences (NASDAQ:DTIL) Stock Price Breaks Below 200 Day Moving Average – Time to Sell? Precision BioSciences, Inc. (NASDAQ: DTIL - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of…
businesswire.com Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
seekingalpha.com Precision BioSciences: Promising HBV Editing Evidence PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral reservoir in patients. Durable off-treatment viral control remains unproven, making the next…
gurufocus.com Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi
businesswire.com Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
businesswire.com Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
zacks.com Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength? Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further…
gurufocus.com Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
businesswire.com Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
gurufocus.com Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
businesswire.com Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing…
